August 6, 2026
Funding Fusion News

Skin longevity beauty brand LNGVTY raises Rs 5 crore from Rukam Capital, angel investors

  • July 20, 2026
  • 0

LNGVTY, a pores and skin longevity magnificence model, has raised Rs 5 crore in a seed funding spherical led by Rukam Capital, a enterprise capital agency centered on

Skin longevity beauty brand LNGVTY raises Rs 5 crore from Rukam Capital, angel investors


LNGVTY, a pores and skin longevity magnificence model, has raised Rs 5 crore in a seed funding spherical led by Rukam Capital, a enterprise capital agency centered on early-stage client startups, with participation from angel traders.

The startup will use the contemporary capital to strengthen D2C advertising and marketing and buyer acquisition, increase the product portfolio, put money into analysis and innovation, and construct the founding crew to speed up the model’s development throughout India.

Talking on the funding, Nishit Ratthe, Founding father of LNGVTY, stated, “I like the wonder class an excessive amount of to observe it swim in mediocrity. I consider longevity is the one true function of magnificence. Your pores and skin is a regenerative organ. Most skincare treats it like a floor to coat. We constructed LNGVTY to assist it do a greater job of regenerating itself.”

“India’s skincare market is coming into a brand new part as customers more and more search science-backed merchandise that ship long-term outcomes. With the market anticipated to almost double over the following decade, we see a major alternative for manufacturers constructed on sturdy scientific foundations. LNGVTY stood out to us for its differentiated biology-first method, clinically backed merchandise and Nishit’s deep understanding of the wonder trade, which gave us the conviction to speculate,” stated Archana Jahagirdar, Founder and Managing Associate, Rukam Capital.

The funding comes as India’s skincare market undergoes a shift in the direction of science-backed and preventive skincare. Valued at greater than USD 9 billion in 2025, the market is projected to succeed in almost $18.4 billion by 2034, pushed by premiumisation, rising client consciousness and rising demand for clinically validated merchandise.